Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML.
Ball B, Xiao W, Borthakur G, Nguyen LXT, Valerio M, Venkatachalam A, Marcucci G, Stein A, Thai DL, Cook D, Chan K, Persaud S, Levine R, Abdel-Wahab O, Ben-Neriah Y, Stein E. Ball B, et al. Among authors: marcucci g. Res Sq [Preprint]. 2024 Oct 15:rs.3.rs-4954060. doi: 10.21203/rs.3.rs-4954060/v1. Res Sq. 2024. PMID: 39483885 Free PMC article. Preprint.
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Bewersdorf JP, et al. Among authors: marcucci g. Leuk Lymphoma. 2023 Jan;64(1):188-196. doi: 10.1080/10428194.2022.2136952. Epub 2022 Oct 26. Leuk Lymphoma. 2023. PMID: 36287540 Free PMC article.
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M. Shimony S, et al. Among authors: marcucci g. Leukemia. 2024 Apr;38(4):762-768. doi: 10.1038/s41375-024-02175-0. Epub 2024 Feb 20. Leukemia. 2024. PMID: 38378841
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.
Zhang Y, Park M, Ghoda LY, Zhao D, Valerio M, Nafie E, Gonzalez A, Ly K, Parcutela B, Choi H, Gong X, Chen F, Harada K, Chen Z, Nguyen LXT, Pichiorri F, Chen J, Song J, Forman SJ, Amanam I, Zhang B, Jin J, Williams JC, Marcucci G. Zhang Y, et al. Among authors: marcucci g. J Hematol Oncol. 2024 Aug 14;17(1):67. doi: 10.1186/s13045-024-01586-x. J Hematol Oncol. 2024. PMID: 39143574 Free PMC article.
OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia.
Kang H, Hoang DH, Valerio M, Pathak K, Zhang L, Buettner R, Chen F, Estrella K, Graff W, Li Z, Xie J, Horne D, Kuo YH, Zhang B, Pirrotte P, Nguyen LXT, Marcucci G. Kang H, et al. Among authors: marcucci g. Leukemia. 2024 Mar;38(3):657-662. doi: 10.1038/s41375-024-02146-5. Epub 2024 Jan 17. Leukemia. 2024. PMID: 38233463 Free PMC article. No abstract available.
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.
Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC. Guzman ML, et al. Among authors: marcucci g. Mol Cancer Ther. 2014 Aug;13(8):1979-90. doi: 10.1158/1535-7163.MCT-13-0963. Epub 2014 Jun 16. Mol Cancer Ther. 2014. PMID: 24934933 Free PMC article.
670 results